1-9 of 9
Anil Londhe
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Characteristics and Outcomes in Patients with Lenalidomide-Refractory Relapsed/Refractory Multiple Myeloma Treated with 1-3 Prior Lines of Therapy: Analysis of the Individual Patient-Level Data from Daratumumab Clinical Trials

Binod Dhakal, Hermann Einsele, Jordan M Schecter, Tito Roccia, William Deraedt, Nikoletta Lendvai, Ana Slaughter, Carolina Lonardi, Kaitlyn Connors, Keqin Qi, Anil Londhe, Robin Carson, Jennifer Voelker, Patricia Cost, Satish Valluri, Erika Florendo, Lida Pacaud, Kwee Yong
Journal: Blood
Blood (2022) 140 (Supplement 1): 4320–4322.
https://doi.org/10.1182/blood-2022-159151
Published: 2022
Journal Articles

Risk Model for Overall Survival for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Validated for Patients on Ibrutinib, Idelalisib, Venetoclax, or Chemoimmunotherapy

Jacob D. Soumerai, MD, Ai Ni, PhD, Mohamed Darif, PhD, Anil Londhe, PhD, Guan Xing, PhD, Yong Mun, PhD, Neil E. Kay, MD, Tait D. Shanafelt, MD, Kari G. Chaffee, MS, Richard R. Furman, MD, Peter Hillmen, MB ChB, PhD FRCP, FRCPath, Jeff Sharman, MD, John F. Seymour, MBBS, PhD, Asher A. Chanan-Khan, MD, John C. Byrd, MD, Jeffrey A. Jones, MD MPH, Lucille A. Ferrante, MD, Lyndah K. Dreiling, MD, Mehrdad Mobasher, MD MPH, Thomas Stark, MD PhD, Vijay Reddy, MD PhD, Angela J. Howes, BSc, PhD, Danelle James, MD MAS, Pankaj Bhargava, MD, Andrew D. Zelenetz, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4394.
https://doi.org/10.1182/blood-2018-99-112989
Published: 2018
Journal Articles

Results of an Interim Safety Analysis of a Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) in Previously Untreated and Relapsed Patients (Pts) with Multiple Myeloma (MM)

Habte Yimer, MD, Jason Melear, MD, Edward Faber, William I. Bensinger, MD, John M Burke, MD, Sriya Gunawardena, MD, Murphy Sean, Hollee Parros, Yana Lutska, Mohamed Darif, PhD, Anil Londhe, PhD, Ming Qi, Jon Ukropec, Thomas Lin, Robert M. Rifkin, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1839.
https://doi.org/10.1182/blood.V130.Suppl_1.1839.1839
Published: 2017
Journal Articles

A Validated Risk Model for Overall Survival in Relapsed/Refractory Chronic Lymphocytic Leukemia Applicable to Patients Treated with Novel Therapies and Standard of Care

Jacob D. Soumerai, MD, Ai Ni, PhD, Mohamed Darif, PhD, Anil Londhe, PhD, Guan Xing, PhD, Julie Huang, PhD, Ming Lin, PhD, John C. Byrd, MD, Asher A. Chanan-Khan, MD, Richard R. Furman, MD, Michael Hallek, MD, Peter Hillmen, MBChB, PhD, Jeffrey Jones, MD, Jeffrey P. Sharman, MD, Lucille Ferrante, MD, Vijay Reddy, MD PhD, Lyndah K. Dreiling, MD, Henry Adewoye, MD, Ronald Dubowy, MD, Angela Howes, PhD, Danelle F. James, MD MAS, Andrew D. Zelenetz, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4303.
https://doi.org/10.1182/blood.V130.Suppl_1.4303.4303
Published: 2017
Journal Articles

Median 3.5-Year Follow-up of Ibrutinib Treatment in Patients with Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis

Simon Rule, MD, Martin Dreyling, MD PhD, Andre Goy, MD, Georg Hess, Rebecca Auer, MD PhD, Brad S Kahl, MD, Jose Angel Hernandez-Rivas, Anil Londhe, PhD, Fong Clow, ScD, Sanjay Deshpande, Lori Parisi, Michael Wang, BS
Journal: Blood
Blood (2017) 130 (Supplement 1): 151.
https://doi.org/10.1182/blood.V130.Suppl_1.151.151
Published: 2017
Journal Articles

Results of an Early Access Treatment Protocol (EAP) of Daratumumab in United States Patients with Relapsed or Refractory Multiple Myeloma

Ajai Chari, MD, Tomer M Mark, MD MSc, Amrita Krishnan, Keith Stockerl-Goldstein, Saad Z Usmani, MD FACP, Anil Londhe, Delores Etheredge, Hollee Parros, Sarah Fleming, Baolian Liu, Scott Freeman, Jon Ukropec, PhD, Thomas Lin, Sagar Lonial, MD FACP
Journal: Blood
Blood (2016) 128 (22): 2133.
https://doi.org/10.1182/blood.V128.22.2133.2133
Published: 2016
Journal Articles

Use of Montelukast to Reduce Infusion Reactions in an Early Access Treatment Protocol of Daratumumab in United States Patients with Relapsed or Refractory Multiple Myeloma

Ajai Chari, MD, Tomer M Mark, MD MSc, Amrita Krishnan, Keith Stockerl-Goldstein, Saad Z Usmani, MD FACP, Anil Londhe, Delores Etheredge, Hollee Parros, Sarah Fleming, Baolian Liu, Scott Freeman, Jon Ukropec, PhD, Thomas Lin, Ajay K Nooka, MD MPH
Journal: Blood
Blood (2016) 128 (22): 2142.
https://doi.org/10.1182/blood.V128.22.2142.2142
Published: 2016
Journal Articles

Safety Results from the United States Cohort of the Ibrutinib Early Access Treatment Protocol (EAP: MCL4001) in Patients with Relapsed or Refractory Mantle Cell Lymphoma

Peter Martin, MD, Andre Goy, MD, Radhakrishnan Ramchandren, MD, Lucille Ferrante, MD, Vijay Reddy, MD PhD, Anil Londhe, Mark Wildgust, Tracy McGowan, MD, Nancy L Bartlett, MD
Journal: Blood
Blood (2014) 124 (21): 4461.
https://doi.org/10.1182/blood.V124.21.4461.4461
Published: 2014
Journal Articles

Impact of Baseline Free Light Chain Ratio (rFLC) On Clinical Outcomes and Change in rFLC During Treatment in Patients with Relapsed/Refractory Multiple Myeloma Treated with Pegylated Liposomal Doxorubicin Plus Bortezomib or Bortezomib Alone.

Valeria Magarotto, MD, Anil Londhe, PhD, Keith C. Lantz, MS, Colin Lowery, DPhil, Pieter Sonneveld, MD, PhD, Joan Bladé, MD, Jean-Luc Harousseau, MD, Robert Z. Orlowski, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 4778.
https://doi.org/10.1182/blood.V114.22.4778.4778
Published: 2009